Epitope-guided Mycobacterium tuberculosis Zmp1 peptide-associated outer membrane vesicles enhance humoral responses to a heterologous antigen SARS-CoV-2 RBD-S2

Enhancing robust antibody responses for applications ranging from vaccine development to commercial antibody production depends on the strategic combination of highly immunogenic antigens and delivery systems that effectively amplify antigen-specific humoral immunity. We observed high titers of Mycobacterium tuberculosis Zmp1 (Mtb Zmp1)-specific antibodies in patients with active tuberculosis (TB), with similarly strong responses in paucibacillary pulmonary and extrapulmonary TB, highlighting the broad humoral immunogenicity of Mtb Zmp1 in our previous studies. We hypothesized that immunoinformatics-guided Zmp1-derived peptides encompassing overlapping predicted B-cell and CD4 + T-cell determinants would improve this antigenic potential and, when delivered in an immunostimulatory platform, could also enhance responses to a co-delivered heterologous antigen. To test this approach, selected Zmp1 peptides or full-length Zmp1 were fused to Escherichia coli ClyA for generating recombinant E. coli ΔnlpI-derived outer membrane vesicles (OMVs), providing an intrinsically immunostimulatory delivery platform. The engineered OMVs formed stable nanoscale vesicles and efficiently incorporated the Zmp1 antigens. All Zmp1-engineered OMV formulations elicited significantly higher Zmp1-specific antibody responses than empty OMVs, confirming that the humoral responses were driven by the Zmp1 antigens. Notably, OMVs associated with the C-terminal Zmp1 region (OMV-CT) generated the strongest Zmp1-specific humoral response, establishing this epitope-enriched region as a potent antigenic component. We next tested whether the Zmp1-engineered OMVs could enhance immunity to a heterologous candidate antigen, SARS-CoV-2 RBD-S2. OMV-CT+RBD-S2 produced the highest RBD-S2-specific antibody titers among the formulations tested, with increased IgG1, IgG2b, and total IgG titers from day 28 that remained elevated through days 42 and 64. This enhanced antibody response was accompanied by relatively higher IL-4 than IFN-γ production and increased CD19 + CD273 + memory B cells and CD4 + CD44 + CD62L + memory T cells, consistent with a Th2-associated response and development of immunological memory. Together, these findings demonstrate that selected Zmp1-derived peptides function as potent antigenic determinants and, when presented within an immunostimulatory OMV platform, can enhance antibody responses to a co-delivered heterologous antigen. These findings highlight the potential of Zmp1 peptide-OMV formulations as versatile adjuvant platforms for promoting robust humoral immunity, supporting the broader use of these formulations with dose and peptide optimization wherever robust humoral immunity is targeted.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-19
DOI
https://doi.org/10.3389/fimmu.2026.1947425
Primary Topic
Tuberculosis Research and Epidemiology
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Epitope-guided Mycobacterium tuberculosis Zmp1 peptide-associated outer membrane vesicles enhance humoral responses to a heterologous antigen SARS-CoV-2 RBD-S2

Abhishek Guggilla, Pramod Rajaram Somvanshi, Krishnaveni Mohareer, Sriram Yandrapally et al.
Frontiers in Immunology
Tuberculosis Research and Epidemiology
article

Epitope-guided Mycobacterium tuberculosis Zmp1 peptide-associated outer membrane vesicles enhance humoral responses to a heterologous antigen SARS-CoV-2 RBD-S2

Abhishek Guggilla, Pramod Rajaram Somvanshi, Krishnaveni Mohareer, Sriram Yandrapally, Sharmistha Banerjee, Simran Srivastava, Raghavan Varadarajan, Warisha Faiz, Saima Naz, Keerthana Choudari, Omkar Shriram Zade, Rajanikant Panda, Akshay Vaijinath Gaikwad, Prabal Basumatary, Rajesh Ringe, Jaya Bharti
article en

Abstract

Enhancing robust antibody responses for applications ranging from vaccine development to commercial antibody production depends on the strategic combination of highly immunogenic antigens and delivery systems that effectively amplify antigen-specific humoral immunity. We observed high titers of Mycobacterium tuberculosis Zmp1 (Mtb Zmp1)-specific antibodies in patients with active tuberculosis (TB), with similarly strong responses in paucibacillary pulmonary and extrapulmonary TB, highlighting the broad humoral immunogenicity of Mtb Zmp1 in our previous studies. We hypothesized that immunoinformatics-guided Zmp1-derived peptides encompassing overlapping predicted B-cell and CD4 + T-cell determinants would improve this antigenic potential and, when delivered in an immunostimulatory platform, could also enhance responses to a co-delivered heterologous antigen. To test this approach, selected Zmp1 peptides or full-length Zmp1 were fused to Escherichia coli ClyA for generating recombinant E. coli ΔnlpI-derived outer membrane vesicles (OMVs), providing an intrinsically immunostimulatory delivery platform. The engineered OMVs formed stable nanoscale vesicles and efficiently incorporated the Zmp1 antigens. All Zmp1-engineered OMV formulations elicited significantly higher Zmp1-specific antibody responses than empty OMVs, confirming that the humoral responses were driven by the Zmp1 antigens. Notably, OMVs associated with the C-terminal Zmp1 region (OMV-CT) generated the strongest Zmp1-specific humoral response, establishing this epitope-enriched region as a potent antigenic component. We next tested whether the Zmp1-engineered OMVs could enhance immunity to a heterologous candidate antigen, SARS-CoV-2 RBD-S2. OMV-CT+RBD-S2 produced the highest RBD-S2-specific antibody titers among the formulations tested, with increased IgG1, IgG2b, and total IgG titers from day 28 that remained elevated through days 42 and 64. This enhanced antibody response was accompanied by relatively higher IL-4 than IFN-γ production and increased CD19 + CD273 + memory B cells and CD4 + CD44 + CD62L + memory T cells, consistent with a Th2-associated response and development of immunological memory. Together, these findings demonstrate that selected Zmp1-derived peptides function as potent antigenic determinants and, when presented within an immunostimulatory OMV platform, can enhance antibody responses to a co-delivered heterologous antigen. These findings highlight the potential of Zmp1 peptide-OMV formulations as versatile adjuvant platforms for promoting robust humoral immunity, supporting the broader use of these formulations with dose and peptide optimization wherever robust humoral immunity is targeted.

Frontiers in ImmunologyVol. 17
University of Hyderabad (IN), National Institute of Pharmaceutical Education and Research (IN), Indian Institute of Science Bangalore (IN)
Tuberculosis Research and Epidemiology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon